Drug Toxicity Clinical Trial
Official title:
Women's Hospital, Zhejiang University School of Medicine
In this study, a prospective, multicenter randomized controlled study was conducted to compare the clinical efficacy and toxicity response of combination MTX+ACTD multi-course regimen in low-risk GTN patients with score 5-6 with standard MTX single-drug multi-course regimen.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Clinical diagnosis of gestational trophoblastic tumor; - Patients with prognosis score of 5 and 6 - Primary chemotherapy (preventive chemotherapy is not included); - Physical strength grade: Karnofsky score = 60; - WBC = 3.5× 109/L, ANC = 1.5× 109/L, PT = 80× 109/L, serum bilirubin = 1.5 times of normal high limit, transaminase = 1.5 times of normal high limit, BUN, Cr= normal; - Follow-up and good compliance; - Sign the informed consent form. Exclusion Criteria: - Pathological diagnosis is intermediate trophoblastic tumor, including PSTT and ETT; - There are serious or uncontrollable medical diseases, which are not suitable for chemotherapy; - Those who receive clinical trials of other drugs at the same time. - Those who receive Chinese medicine. |
Country | Name | City | State |
---|---|---|---|
China | Weiguo Lv | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Women's Hospital School Of Medicine Zhejiang University | Huazhong University of Science and Technology, Qilu Hospital of Shandong University, West China Second University Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | primary complete remission | complete remission rate by primary treatment | 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
Recruiting |
NCT04696081 -
Atrial Fibrillation in Active Cancer Patients
|
||
Active, not recruiting |
NCT03651778 -
GHB Poisoning and Poisoning Induced by Others
|
||
Completed |
NCT04120233 -
MW151-101: First-in-human Study of MW151
|
Phase 1 | |
Recruiting |
NCT01965275 -
High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs
|
Phase 2 | |
Completed |
NCT01614080 -
Outcome of Patients Treated by iv Rt-PA for Cerebral Ischaemia According to the Ratio Sc-tPA/Tc-tPA
|
N/A | |
Recruiting |
NCT04659343 -
TDM for Optimized Outcome in Patients With mRCC.
|
||
Completed |
NCT02864030 -
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
|
Phase 4 | |
Completed |
NCT01135680 -
Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100
|
Phase 1 | |
Completed |
NCT03947034 -
Monitoring the Hyperammonaemia:TOXicity of Drugs (AmmoTOX)
|
||
Completed |
NCT00491595 -
Phase I Clinical Study of Soy Isoflavones in Healthy, Post-Menopausal Women
|
Phase 1 | |
Recruiting |
NCT03469063 -
Impact of AferBio® on Quality of Life and Chemotherapy Toxicity in Lung Cancer Patients
|
N/A | |
Not yet recruiting |
NCT04671589 -
Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic.
|
Phase 4 | |
Completed |
NCT03280368 -
Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation
|
||
Withdrawn |
NCT01374061 -
Pre Hospital Evaluation of Video Laryngoscopy
|
Phase 4 | |
Completed |
NCT03994302 -
Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (APSTOX)
|
||
Completed |
NCT03392311 -
Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
Terminated |
NCT00090844 -
Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer
|
Phase 2 | |
Terminated |
NCT00213642 -
Tc-99m Renography and Cisplatin-induced Nephrotoxicity
|
N/A | |
Recruiting |
NCT05022797 -
Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS
|
Phase 2 |